Research Underway on Novel Lung Cancer Radiotherapy Treatment
By MedImaging International staff writers Posted on 06 Apr 2015 |
Potentially ground-breaking research is intended to find the role of Stereotactic Ablative Radiotherapy (SABR)/Stereo-Tactic Body Radiation (STBR) therapy in the treatment of bulkier Non-Small-Cell Lung Cancer (NSCLC).
According to West Virginia University (Morgantown, WV, USA) thoracic radiation oncologist Alexander Chi, MD, principal investigator of the study, the researchers will try to validate the use of intensity modulated, image-guided photon therapy for dose escalation to help treat local-regionally confined NSCLC.
Two trials are currently underway, one is a phase II clinical trial investigating the role of SABR in the treatment of large, early stage NSCLC, using a higher than normal Biologically Effective Dose (BED), and the second is a phase I clinical trial for the treatment of locally advanced NSCLC, by delivering a stereo-tactic boost, before or after concurrent chemo-radiation therapy.
The researchers are also investigating which patients could benefit from dose escalation, and those who may need further systemic therapy for individual treatment strategies based on their individual genetic profile.
Related Links:
West Virginia University
According to West Virginia University (Morgantown, WV, USA) thoracic radiation oncologist Alexander Chi, MD, principal investigator of the study, the researchers will try to validate the use of intensity modulated, image-guided photon therapy for dose escalation to help treat local-regionally confined NSCLC.
Two trials are currently underway, one is a phase II clinical trial investigating the role of SABR in the treatment of large, early stage NSCLC, using a higher than normal Biologically Effective Dose (BED), and the second is a phase I clinical trial for the treatment of locally advanced NSCLC, by delivering a stereo-tactic boost, before or after concurrent chemo-radiation therapy.
The researchers are also investigating which patients could benefit from dose escalation, and those who may need further systemic therapy for individual treatment strategies based on their individual genetic profile.
Related Links:
West Virginia University
Latest Nuclear Medicine News
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure